Wouter. B. N.
- Country
- The Netherlands
- Department
- Gastroenterology and Hepatology
Research Overview
- Evaluation of Safety, Feasibility, and Optimal Dosing of Fluorescently Labeled Adalimumab-680LT in Patients with Inflammatory Bowel Disease
- Evaluation of Risankizumab-800CW Safety and Optimal Imaging Dose in Inflammatory Bowel Disease Using Fluorescence Molecular Endoscopy
- Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory Bowel Diseases (VOYAGER)
Data & Insights
Has run more than one trial at 1 of 1 partner site.
Specializations
Inflammatory Bowel Disease
The investigator studies chronic intestinal inflammation, focusing on therapeutic strategies for Crohn's disease and ulcerative colitis.
- Biologic therapy optimization
- Fistula management protocols
- Mucosal healing assessment
Emphasis is placed on endoscopic outcomes and patient‑reported quality of life.
Hepatology & Liver Oncology
Research includes chronic liver disease and primary liver cancers, such as alcoholic cirrhosis and hepatocellular carcinoma.
- Antifibrotic agent evaluation
- Immunotherapy in HCC
- Biomarker‑driven clinical trials
Integration of advanced imaging and transplant eligibility criteria guides therapeutic decisions.
Systemic Autoimmune & Vasculitis
Focus on systemic immune‑mediated disorders, notably systemic lupus erythematosus, ANCA‑associated vasculitis, and IgG4‑related disease.
- Targeted cytokine inhibition
- Renal involvement management
- Long‑term safety monitoring
Collaboration with rheumatology supports multidisciplinary patient care.
Hematologic Malignancies
Engagement in trials for aggressive blood cancers, including diffuse large B‑cell lymphoma and acute myeloid leukemia.
- CAR‑T cell therapy development
- Novel kinase inhibitor assessment
- Transplant conditioning regimen optimization
Molecular profiling is leveraged to personalize therapeutic approaches.
Cardiometabolic & Renal Intersections
Studies address cardiovascular and kidney disease overlap, such as chronic kidney disease with hypertension and heart failure with preserved ejection fraction.
- Renal protective agent trials
- SGLT2 inhibitor efficacy studies
- Biomarker discovery for cardiorenal risk
Integrated care pathways within the same academic centre facilitate comprehensive management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.